Following ChatGPT Announcement, These Artificial Intelligence Focused ETFs Show Strong Gains

Microsoft Corp (NASDAQ: MSFT) backed OpenAI's ChatGPT chatbot, which grabbed the attention of the global tech sector in early 2023, adept at answering questions and writing essays and poems, and image generator Dall-E 2, which turns language prompts

Microsoft Corp (NASDAQ:MSFT) backed OpenAI’s ChatGPT chatbot, which grabbed the attention of the global tech sector in early 2023, adept at answering questions and writing essays and poems, and image generator Dall-E 2, which turns language prompts into novel images.

The AI industry almost triggered a battle among the big tech companies like Microsoft and Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGLGoogle in their bid to outdo each other. It mainly came when companies were busy downsizing their workforce and shelving projects and real estate presence amid macro uncertainties.

The ETFs with significant exposure to the ChatGPT stocks made handsome gains year-to-date.

SPDR Select Sector Fund – Technology (NYSE: XLK), iShares Global Tech ETF (NYSE: IXN), and Fidelity MSCI Information Technology Index ETF (NYSE: FTEC) gained ~20% YTD. The ETFs gained 15%-18% in the last six months and 5% the previous month.

The ETFs have 18%-24% exposure to Microsoft, 22%-23% exposure to Apple Inc (NASDAQ: AAPL), and 5%-6% exposure to Nvidia. Apple maintained a low profile in terms of its ChatGPT ambitions.

Analysts touted Nvidia Corp (NASDAQ:NVDA) as a critical gainer from the ChatGPT wave.

Microsoft’s new AI additions to its Bing search engine bore mixed results in February. Colossal AI search costs posed as additional headwinds. 

Last week, OpenAI made ChatGPT capable of web browsing.

This week, China’s Baidu Inc (NASDAQ:BIDU) dumped the highly-anticipated public launch of its ChatGPT-like product, Ernie Bot

Baidu’s cancellation came weeks after founder Robin Li disappointed by marking Ernie Bot’s debut via recorded video instead of a real-time demo.

Total
0
Shares
Related Posts
Read More

BioCryst And Clearside Biomedical Enter Partnership To Develop Avoralstat For Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector; SCS Microinjector Is The First And Only FDA-Approved Approach To Access The Suprachoroidal Space

– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space – – BioCryst to host R&D Day today at 1:00 pm ET –ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03,

BCRX

Read More

3 Minutes To Boost Your Earnings: 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street’s Most Accurate Analysts

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

NAT